Brokerages expect PerkinElmer, Inc. (NYSE:PKI) to announce $552.30 million in sales for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made estimates for PerkinElmer’s earnings, with estimates ranging from $550.00 million to $553.20 million. PerkinElmer reported sales of $548.05 million during the same quarter last year, which indicates a positive year over year growth rate of 0.8%. The firm is expected to issue its next quarterly earnings report on Monday, November 6th.

According to Zacks, analysts expect that PerkinElmer will report full year sales of $552.30 million for the current financial year, with estimates ranging from $2.21 billion to $2.24 billion. For the next financial year, analysts forecast that the business will report sales of $2.32 billion per share, with estimates ranging from $2.30 billion to $2.34 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover PerkinElmer.

PerkinElmer (NYSE:PKI) last posted its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.67 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.67. PerkinElmer had a net margin of 16.80% and a return on equity of 13.44%. The business had revenue of $547.00 million during the quarter, compared to the consensus estimate of $554.14 million. During the same period in the previous year, the firm posted $0.67 earnings per share. The business’s revenue for the quarter was up 2.0% compared to the same quarter last year.

Several research analysts have issued reports on PKI shares. Cantor Fitzgerald reissued a “hold” rating on shares of PerkinElmer in a research report on Sunday, July 16th. Zacks Investment Research raised shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $78.00 price objective on the stock in a research report on Wednesday, July 19th. Piper Jaffray Companies raised their price objective on shares of PerkinElmer to $80.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 25th. Wells Fargo & Company started coverage on shares of PerkinElmer in a research report on Thursday, July 13th. They set a “market perform” rating and a $72.00 price objective on the stock. Finally, Morgan Stanley reissued an “overweight” rating and set a $79.00 price objective (up from $73.00) on shares of PerkinElmer in a research report on Monday, July 10th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the stock. PerkinElmer presently has a consensus rating of “Hold” and an average price target of $67.92.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Envestnet Asset Management Inc. increased its holdings in PerkinElmer by 28.1% during the 1st quarter. Envestnet Asset Management Inc. now owns 1,979 shares of the medical research company’s stock valued at $115,000 after acquiring an additional 434 shares in the last quarter. Acrospire Investment Management LLC increased its holdings in PerkinElmer by 185.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,000 shares of the medical research company’s stock valued at $136,000 after acquiring an additional 1,300 shares in the last quarter. Ameritas Investment Partners Inc. purchased a new position in PerkinElmer during the 1st quarter valued at about $152,000. LS Investment Advisors LLC increased its holdings in PerkinElmer by 2.1% during the 2nd quarter. LS Investment Advisors LLC now owns 2,877 shares of the medical research company’s stock valued at $196,000 after acquiring an additional 60 shares in the last quarter. Finally, Carret Asset Management LLC purchased a new position in PerkinElmer during the 2nd quarter valued at about $210,000. Hedge funds and other institutional investors own 91.47% of the company’s stock.

Shares of PerkinElmer (NYSE:PKI) opened at 70.44 on Friday. The firm has a market capitalization of $7.76 billion, a P/E ratio of 21.24 and a beta of 0.72. The stock’s 50 day moving average is $67.53 and its 200 day moving average is $64.26. PerkinElmer has a 1-year low of $45.35 and a 1-year high of $70.59.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 10th. Investors of record on Friday, October 20th will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.40%. The ex-dividend date is Thursday, October 19th. PerkinElmer’s dividend payout ratio (DPR) is 8.46%.

TRADEMARK VIOLATION WARNING: This report was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/06/brokerages-anticipate-perkinelmer-inc-pki-will-post-quarterly-sales-of-552-30-million-2.html.

About PerkinElmer

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Get a free copy of the Zacks research report on PerkinElmer (PKI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.